The musician-turned-biotech-founder waiting to fundraise
THE SO WHAT
Biotech is reminding operators that money without a commercialization and regulatory path is just expensive hope. If you’re building in regulated tech — AI in health, finance, infra — treat your go-to-market and compliance architecture as part of the science, not an afterthought to bolt on once a celebrity check clears.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging Tech'Maybe it’s not science fiction': Solar panels are causing rainwater to fall in one of the driest places on Earth
If large solar farms are measurably changing local rainfall patterns, energy siting becomes a climate-engineering decision, not just a land-use one. Utilities and developers need to model atmospheric impacts alongside grid and tax economics or risk a backlash that slows deployment in exactly the deserts they’re counting on.
Deep & Emerging TechASML Won’t Be an AI Bottleneck, Says Berenberg's Qiu
If ASML isn’t the constraint, the choke points move further down the stack—to power, packaging, and system integration. Infra planners need to stop using “lithography bottleneck” as an excuse and start modeling where the real limits to AI capacity will show up in 2027 and beyond.
Deep & Emerging TechFDA weighs support for compounding popular peptides
If the FDA greenlights compounding for a subset of peptides, the line between pharma, wellness, and gray-market biohacking blurs fast. Health and longevity startups should assume a more permissive peptide environment and design offerings that survive a later regulatory snapback.
Deep & Emerging TechAmazon to Buy Satellite Company Globalstar for $11.6B
Amazon spending $11.6B for Globalstar is a bet that control of orbital bandwidth and backhaul will matter as much as data centers for its next decade of services. If your product assumes cheap, neutral satellite connectivity, start modeling a world where hyperscalers own the pipes end to end.